Full history for every metric is available with a Kvantra account
Key financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CHF m | 192 | 234 | 277 | 320 | 361 | 333 | 363 | 396 |
| Operating profit | CHF m | 25 | 39 | ||||||
| Net profit | CHF m | 5 | 11 | 19 | 26 | 39 | 16 | 30 | 32 |
| EPS reported | CHF | 0.72 | 1.33 | ||||||
| Operating cashflow per share | CHF | 2.85 | 2.57 | ||||||
| Capex per share | CHF | 1.92 | 1.62 | ||||||
| FCF per share | CHF | 0.93 | 0.96 | ||||||
| Free cash flow | CHF m | 21 | 22 | ||||||
| Net debt | CHF m | 33 | 42 | ||||||
| Book value equity | CHF m | 114 | 114 | ||||||
| Book value per share | CHF | 5.09 | 5.06 | ||||||
| Number of shares | m | 22.48 | 22.48 | ||||||
| DPS (TTM paid) | CHF | 0.22 | 0.22 |
Financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 73.33 | - | ||||||
| P/B LTM | x | 10.37 | 13.41 | ||||||
| P/S LTM | x | 3.56 | 4.20 | ||||||
| P/FCF LTM | x | 56.51 | 70.82 | ||||||
| EV/EBITDA LTM | x | 33.99 | 26.83 | ||||||
| EV/Sales LTM | x | 3.67 | 4.31 | ||||||
| Earnings Yield LTM | % | 1.36% | 1.97% | ||||||
| FCF Yield | % | 1.77% | 1.41% | ||||||
| Quality | |||||||||
| ROE | % | 14.22% | 26.29% | ||||||
| ROIC | % | 7.65% | 7.17% | ||||||
| Operating margin | % | 7.63% | 10.74% | ||||||
| Gross margin | % | 69.09% | 69.15% | ||||||
| FCF/Sales | % | 6.30% | 5.93% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -58.38% | +84.72% | ||||||
| Sales Growth YoY | % | -7.74% | +9.37% | ||||||
| Net Income Growth YoY | % | -58.06% | +85.36% | ||||||
| FCF Growth | % | - | +17.11% | ||||||
| Operating Profit Growth | % | -42.84% | +59.97% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.76% | 0.32% | ||||||
| Dividend Growth | % | -45.00% | -45.00% | ||||||
| Payout Ratio | % | 55.55% | 55.26% | ||||||
| FCF/Debt | x | 0.16 | 0.16 | ||||||
| Net Debt/EBITDA | x | 1.04 | 0.72 | ||||||
| EBIT/Net interest | x | 17.09 | 4.33 | ||||||
| Net debt/market cap | % | 2.74% | 2.77% | ||||||
| Net debt/Equity | x | 0.28 | 0.37 | ||||||
| Gross debt/equity | x | 1.15 | 1.15 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
SKAN Group AG is a global leader specializing in critical solutions for the pharmaceutical and chemical sectors, offering advanced isolators, cleanroom technologies, and decontamination processes across Asia, Europe, and the Americas. The company operates through two distinct divisions: Equipment and Solutions (E&S), and Services and Consumables (S&C). Its E&S segment delivers essential products for pharmaceutical manufacturing, including high-tech isolators, integrated automated systems, aseptic filling solutions, and specialized laboratory and cleanroom equipment. Meanwhile, the S&C segment focuses on providing comprehensive life cycle support, ready-to-use consumables, and custom digital and client-specific solutions. Founded in 1968, the company, which changed its name from BV Holding AG to SKAN Group AG in October 2021, is headquartered in Allschwil, Switzerland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
SKAN Group AG is a global leader specializing in critical solutions for the pharmaceutical and chemical sectors, offering advanced isolators, cleanroom technologies, and decontamination processes across Asia, Europe, and the Americas. The company operates through two distinct divisions: Equipment and Solutions (E&S), and Services and Consumables (S&C). Its E&S segment delivers essential products for pharmaceutical manufacturing, including high-tech isolators, integrated automated systems, aseptic filling solutions, and specialized laboratory and cleanroom equipment. Meanwhile, the S&C segment focuses on providing comprehensive life cycle support, ready-to-use consumables, and custom digital and client-specific solutions. Founded in 1968, the company, which changed its name from BV Holding AG to SKAN Group AG in October 2021, is headquartered in Allschwil, Switzerland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free